Literature DB >> 9618256

Complete amino acid sequence of the B chain of mistletoe lectin I.

M H Soler1, S Stoeva, W Voelter.   

Abstract

The primary structure of the B chain of mistletoe lectin I, the component of a commercially available extract from Viscum album exhibiting immunomodulatory capacity, was established based on amino acid sequence analysis of the protein and peptides derived from its enzymatic digestion. It is composed of 264 residues, including seven cysteine residues and three N-linked carbohydrate chains. The amino acid sequence of MLB shows a high homology with those from other structurally related galactoside-specific lectins such as ricin and abrin with 169 and 146 identities, respectively. These results are of crucial importance in order to understand the biological activity of ML-1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618256     DOI: 10.1006/bbrc.1998.8670

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Ricin and viscumin bind to different sites of the cell membrane.

Authors:  M M Moisenovich; I A Demina; I I Agapov; O V Chelnokova; N V Kozlovskaya; J Bereiter-Hahn; A G Tonevitsky; V I Shumakov
Journal:  Dokl Biol Sci       Date:  2002 Mar-Apr

2.  Unexpected different binding of mistletoe lectins from plant extracts to immobilized lactose and N-acetylgalactosamine.

Authors:  Tibor Hajtò; Fodor Krisztina; Aponyi Ildikò; Pallai Zsolt; Balogh Pèter; Németh Pèter; Perjési Pàl
Journal:  Anal Chem Insights       Date:  2007-09-17

3.  [Paraoxonase 1 gene polymorphism 192Q/R in old men and long-livers from Tatars ethnic group].

Authors:  V V Pauk; I A Tuktarova; T R Nasibullin; L P Zueva; A Kh Adel'guzhina; E K Khusnutdinova; O E Mustafina
Journal:  Mol Biol (Mosk)       Date:  2007 Jul-Aug

4.  Oncopharmacological Perspectives of a Plant Lectin (Viscum album Agglutinin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications.

Authors:  Tibor Hajtó; Katarina Hostanska; Timea Berki; László Pálinkás; Ferenc Boldizsár; Péter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2005-01-28       Impact factor: 2.629

5.  Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine.

Authors:  Tibor Hajtó; Krisztina Fodor; Pál Perjési; Pèter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-09       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.